New drug duo tested for aggressive blood cancer

NCT ID NCT06192888

Summary

This early-stage study is testing whether combining two drugs, glofitamab and lenalidomide, is a safe and feasible treatment for adults with mantle cell lymphoma that has come back or stopped responding to other therapies. It is specifically for people whose cancer progressed after treatment with a type of drug called a BTK inhibitor. The main goal is to see if patients can successfully receive the full planned doses of the new combination.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dana Farber Cancer Institute (Data Collection and Specimen Analysis)

    Boston, Massachusetts, 02115, United States

  • Mayo Clinic (Data Collection Only)

    Rochester, Minnesota, 55905, United States

  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities)

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Monmouth (Limited protocol activities)

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau (All protocol activities)

    Rockville Centre, New York, 11553, United States

  • Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Westchester (Limited protocol activities)

    Harrison, New York, 10604, United States

  • Washington University (Data Collection Only)

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.